Effectiveness of anti-PD-1 for hepatocellular carcinoma - Authors' reply

Affiliations

¹ Cancer Centre of Jinling Hospital, Nanjing 210002, China. Electronic address: qinsk@csco.org.cn.
² Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
³ Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Shanghai, China.
⁴ Department of Medical Oncology, Second Hospital of Anhui Medical University, Hefei, China.
⁵ Department of Intervention, Hunan Cancer Hospital, Changsha, China.

Comment

Shukui Qin et al. Lancet Oncol. 2020 Jun.

. 2020 Jun;21(6):e294.

doi: 10.1016/S1470-2045(20)30285-0.

¹ Cancer Centre of Jinling Hospital, Nanjing 210002, China. Electronic address: qinsk@csco.org.cn.
² Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
³ Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Shanghai, China.
⁴ Department of Medical Oncology, Second Hospital of Anhui Medical University, Hefei, China.
⁵ Department of Intervention, Hunan Cancer Hospital, Changsha, China.

No abstract available

Comment on

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Chen C, Zou J. Qin S, et al. Lancet Oncol. 2020 Apr;21(4):571-580. doi: 10.1016/S1470-2045(20)30011-5. Epub 2020 Feb 26. Lancet Oncol. 2020. PMID: 32112738 Clinical Trial.
Effectiveness of anti-PD-1 for hepatocellular carcinoma.
Liao R. Liao R. Lancet Oncol. 2020 Jun;21(6):e293. doi: 10.1016/S1470-2045(20)30170-4. Lancet Oncol. 2020. PMID: 32502446 No abstract available.